Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use

<p><b>Declarations</b></p> <p><b>Funding</b> The preparation of this review was not supported by any external funding.</p> <p><b>Authorship and Conflict of interest</b> Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p> </p> <b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability </b>Not applicable.<div><br></div><div>Additional information about this Adis Drug Review can be found <a href="https://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a>.<br></div><div><br></div><div>Abstract</div><div><p>Moxetumomab pasudotox (Lumoxiti^®), an anti-CD22 recombinant immunotoxin, is an important treatment option that is approved in adults with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior lines of treatment with systemic therapies including purine nucleoside analogues. In a pivotal phase III trial, treatment with moxetumomab pasudotox resulted in approximately one third of patients achieving durable complete response lasting more than 6 months, as well as improvements in other haematological parameters and disease-related symptoms. Moxetumomab pasudotox had a generally manageable tolerability profile; the most common treatment-related adverse events (AEs) included nausea, peripheral oedema, headache and pyrexia. AEs of special interest (including haemolytic uraemic syndrome and capillary leak syndrome) were generally manageable and reversible with monitoring and supportive care.</p><p>© Springer Nature Switzerland AG 2021</p></div>